Posted by Michael Wonder on 16 Dec 2024
CSL receives positive CHMP opinion for garadacimab in hereditary angioedema
13 December 2024 - If approved, garadacimab will be the first and only once monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years
CSL today announced the EMA's CHMP adopted a positive opinion, recommending granting a marketing authorisation for garadacimab as a once-monthly prophylactic treatment for hereditary angioedema in adult and adolescent patients aged 12 years and older.
